CN Patent

CN110151731A — 用于治疗注意力缺陷障碍的方法和组合物

Assigned to Ironshore Pharmaceuticals and Development Inc Cayman Island · Expires 2019-08-23 · 7y expired

What this patent protects

用于治疗注意力缺陷障碍(ADD)或注意力缺陷多动障碍(ADHD)的治疗组合物和方法，其包括以延迟和控制释放制剂递送治疗量的活性药物的剂型。所述剂型可以在晚上给药，并且药物释放延迟3至8小时，接着释放速率递增。

USPTO Abstract

用于治疗注意力缺陷障碍(ADD)或注意力缺陷多动障碍(ADHD)的治疗组合物和方法，其包括以延迟和控制释放制剂递送治疗量的活性药物的剂型。所述剂型可以在晚上给药，并且药物释放延迟3至8小时，接着释放速率递增。

Drugs covered by this patent

methylphenidate-hydrochloride (METHYLPHENIDATE HYDROCHLORIDE)

Patent Metadata

Patent number: CN110151731A
Jurisdiction: CN
Classification: —
Expires: 2019-08-23
Drug substance claim: No
Drug product claim: No
Assignee: Ironshore Pharmaceuticals and Development Inc Cayman Island
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.